TY - JOUR
T1 - National survey on status of steroid therapy for cardiac sarcoidosis in Japan
AU - Hiramitsu, Shinya
AU - Morimoto, Shin Ichiro
AU - Uemura, Akihisa
AU - Kato, Yasuchika
AU - Kimura, Katsutomo
AU - Ohtsuki, Masatsugu
AU - Kato, Shigeru
AU - Sugiura, Atsushi
AU - Miyagishima, Kenji
AU - Hishida, Hitoshi
AU - Sugisaki, Katsunori
AU - Tsuda, Tomiyasu
PY - 2005/10
Y1 - 2005/10
N2 - Aim: This investigation was undertaken to clarify the current status of steroid therapy for cardiac sarcoidosis in Japan. Methods: A questionnaire survey was conducted throughout Japan concerning cases in which steroid therapy had been administered. Replies describing 52 cases (15 men, 37 women; mean age ± SD, 59.8 ± 14.5 years) were analyzed. Results: Of the 49 patients whose New York Heart Association (NYHA) functional classification was reported, 29 (55.8%) were in class I; 13 (25.0%) class II; 4 (7.7%) class III and 3 (5.8%) class IV. The most common initial steroid dose (used in 35 cases, or 67.3%) was 30 mg/day or 60 mg on alternate days. In most cases (85.4%), this dose was continued for 1 month followed by tapering by 5 mg every 2 to 4 weeks until reaching the maintenance dose of 5 to 10 mg/day. Steroid therapy was reported to result in improvement in 54%, no change in 40%, and deterioration in 6%. Conclusion: This nationwide questionnaire survey indicated fairly uniform patterns of steroid therapy for cardiac sarcoidosis in Japan, with clinical improvement in over one-half of cases and possible stabilization in most others.
AB - Aim: This investigation was undertaken to clarify the current status of steroid therapy for cardiac sarcoidosis in Japan. Methods: A questionnaire survey was conducted throughout Japan concerning cases in which steroid therapy had been administered. Replies describing 52 cases (15 men, 37 women; mean age ± SD, 59.8 ± 14.5 years) were analyzed. Results: Of the 49 patients whose New York Heart Association (NYHA) functional classification was reported, 29 (55.8%) were in class I; 13 (25.0%) class II; 4 (7.7%) class III and 3 (5.8%) class IV. The most common initial steroid dose (used in 35 cases, or 67.3%) was 30 mg/day or 60 mg on alternate days. In most cases (85.4%), this dose was continued for 1 month followed by tapering by 5 mg every 2 to 4 weeks until reaching the maintenance dose of 5 to 10 mg/day. Steroid therapy was reported to result in improvement in 54%, no change in 40%, and deterioration in 6%. Conclusion: This nationwide questionnaire survey indicated fairly uniform patterns of steroid therapy for cardiac sarcoidosis in Japan, with clinical improvement in over one-half of cases and possible stabilization in most others.
KW - Cardiac sarcoidosis
KW - Corticosteroid therapy
KW - Questionnaire
UR - https://www.scopus.com/pages/publications/27944471885
UR - https://www.scopus.com/pages/publications/27944471885#tab=citedBy
M3 - Review article
C2 - 16315784
AN - SCOPUS:27944471885
SN - 1124-0490
VL - 22
SP - 210
EP - 213
JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases
JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases
IS - 3
ER -